Professor

XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC)

Retrieved on: 
Tuesday, January 30, 2024

MARKHAM, ON, Jan. 30, 2024 /CNW/ - Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting.

Key Points: 
  • MARKHAM, ON, Jan. 30, 2024 /CNW/ - Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting.
  • "I welcome the approval of XTANDI as a promising earlier treatment option for eligible patients.
  • This marks a significant step forward in addressing unmet needs for prostate cancer treatment."
  • With our recent acquisition of Propella Therapeutics, Inc., we strive to achieve even more in the investigation of targeted prostate cancer treatments for patients of the future."

Pressure BioSciences Reports New Client Launching Around UltraShear Nanoemulsions Platform with $300,000-plus Product Order

Retrieved on: 
Thursday, January 18, 2024

The company’s website and online store are currently under construction, with the initial PrescriptionGrade products slated for Beta testing in March 2024, and fully launching into sales in Q2 2024.

Key Points: 
  • The company’s website and online store are currently under construction, with the initial PrescriptionGrade products slated for Beta testing in March 2024, and fully launching into sales in Q2 2024.
  • VICAR has proudly announced PBIO’s Nano-CBD Topical Spray will be the first product available through their on-line store.
  • Manufactured using PBIO’s patented UltraShear™ technology (UltraShear™ or UST™), PrescriptionGrade Nano-CBD is a revolutionary high-performance product providing ultrafast speed of action and unprecedented effectiveness, in a preservative-free, “green/clean” labeled, sterile-filtered and vialed, all plant-based, highly stable topical product design.
  • Our commitment to excellence extends well beyond the all-important formulation, encompassing iconic branding and streamlined order flow systems.

Global Leaders and Civic Courage Demand Justice for Nobel Laureate Muhammad Yunus

Retrieved on: 
Monday, January 29, 2024

In their letter, the leaders noted with concern "….the rushed legal process, and lack of consistency with regard to how Bangladesh's laws are applied.

Key Points: 
  • In their letter, the leaders noted with concern "….the rushed legal process, and lack of consistency with regard to how Bangladesh's laws are applied.
  • "I call on the Prime Minister to stop this senseless campaign against Professor Muhammad Yunus now."
  • "A social activist and Nobel laureate," Irene Khan warned, "who brought honor and pride to the country is being persecuted on frivolous grounds."
  • Sam Daley-Harris, the founder of Civic Courage, urged concerned citizens to respond to this call to action .

World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

Retrieved on: 
Tuesday, January 23, 2024

It is proven to help patients lose an average of 10-15% of their body weight after approximately four months2.

Key Points: 
  • It is proven to help patients lose an average of 10-15% of their body weight after approximately four months2.
  • Studies show that on average, 96% of weight loss can be sustained 1 year after the balloon passes3.
  • The first two patients to receive the treatment were treated at Somerset NHS Foundation Trust’s (FT) Musgrove Park Hospital in November, under the care of Professor Richard Welbourn, consultant bariatric surgeon at Somerset NHS Foundation Trust.
  • “People with severe obesity are prone to diseases, such as type 2 diabetes, which can be reversed with weight loss.

Lights, Cancer, Action! Sahmyook University Researchers Develop a Light-Responsive Novel Drug Delivery System Against Skin Cancer

Retrieved on: 
Thursday, January 25, 2024

SEOUL, South Korea, Jan. 25, 2024 /PRNewswire/ -- Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage. Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin cancer. By incorporating gold nanorods into the matrix of nanofibers, the study demonstrates external control over the release of anticancer drugs in a sequential and controlled method. This innovative DDS holds promise for future real-life nanotech-based applications in healthcare.

Key Points: 
  • SEOUL, South Korea, Jan. 25, 2024 /PRNewswire/ -- Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage.
  • Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin cancer.
  • In this light, a team of researchers led by Professor Myoung-Hwan Park from Sahmyook University in South Korea has developed a light-responsive nanofiber-based novel drug delivery system (DDS) targeting skin cancer.
  • Accordingly, the integration of nanofibers with on-demand drug delivery systems can open up new possibilities for drug therapy."

Robert S. Langer, Co-Founder of Moderna, Joins Lindus Health's Advisory Board

Retrieved on: 
Thursday, January 25, 2024

Dr. Langer has received more than 220 major awards, has authored over 1,570 articles, and has more than 1,400 patents issued and pending globally.

Key Points: 
  • Dr. Langer has received more than 220 major awards, has authored over 1,570 articles, and has more than 1,400 patents issued and pending globally.
  • These patents have been licensed or sublicensed to over 400 companies spanning pharmaceuticals, chemicals, biotechnology, and medical devices.
  • He is the most cited engineer in history (h-index 319 with more than 412,500 citations according to Google Scholar).
  • Michael Young, co-founder of Lindus Health said: "We are incredibly humbled to welcome Dr. Langer to our advisory board.

GIST Researchers Investigate Strange Transient Responses of Organic Electrochemical Transistors

Retrieved on: 
Tuesday, January 23, 2024

GWANGJU, South Korea, Jan. 23, 2024 /PRNewswire/ -- Organic mixed ionic–electronic conductors (OMIECs) are a highly sought-after class of materials for non-conventional applications, such as bioelectronics, neuromorphic computing, and bio-fuel cells, owing to their two-in-one electronic and ionic conduction properties. To ensure a much wider acceptance of these fascinating materials, there is a need to diversify their properties and develop techniques that allow application-specific tailoring of the features of OMIEC-based devices. A crucial aspect of this process is to develop strategies for evaluating the various properties of these materials. However, despite the increasing popularity of OMIECs, there is a severe lack of research on the molecular orientation-dependent transient behaviors of such conductors.

Key Points: 
  • However, despite the increasing popularity of OMIECs, there is a severe lack of research on the molecular orientation-dependent transient behaviors of such conductors.
  • In their recent breakthrough study published in Nature Communications on 28 November 2023, the team explored peculiar transient behaviors of OMIECs governed by variations in molecular orientation with the help of an organic electrochemical transistor (OECT).
  • We decided to investigate the correlation between backbone planarity-dependent molecular orientation and transient OECT characteristics."
  • To this end, the researchers first synthesized two new 1,4-dithienylphenylene (DTP)-based OMEICs, DTP-2T and DTP-P, with co-monomer units, 2,2'-bithiophene and phenylene, respectively.

Vantage UK Releases Groundbreaking Episode of The Vantage View: Exploring the Circular Economy

Retrieved on: 
Friday, January 19, 2024

LONDON, Jan. 19, 2024 /PRNewswire/ -- Vantage (or Vantage Markets), an award-winning multi-asset broker, is thrilled to launch the second episode of video series, The Vantage View, centred on the circular economy.

Key Points: 
  • LONDON, Jan. 19, 2024 /PRNewswire/ -- Vantage (or Vantage Markets), an award-winning multi-asset broker, is thrilled to launch the second episode of video series, The Vantage View, centred on the circular economy.
  • This episode features Dr Seeram Ramakrishna, Professor and Director of the Centre for Nanotechnology and Sustainability, National University of Singapore.
  • Dr Ramakrishna explores the difference between the linear economy which the modern economy is based on, and the circular economy which offers a greater benefit to society.
  • "The rise of the circular economy presents a sustainable shift from traditional business practices, aligning with Vantage's progression towards ESG principles and bolstering our support for both UNHCR and the Vantage Foundation," said David Shayer, CEO of Vantage UK.

GIST Researchers Optimize the Performance of Novel Organic Electrochemical Transistors

Retrieved on: 
Thursday, January 18, 2024

The steady-state performance of OECTs can be optimized by using both molecular design and structural alignment together to reduce the energetic and microstructural disorders in the films.

Key Points: 
  • The steady-state performance of OECTs can be optimized by using both molecular design and structural alignment together to reduce the energetic and microstructural disorders in the films.
  • Talking to us about the rationale behind conducting this study, Prof. Yoon says, "Using mixed conductors in electrochemical transistors makes it difficult to expect significant performance improvements, even when applying conventional microstructure control processes.
  • Organic mixed conductors are among the most promising materials in this field, with high potential for advancement.
  • Our research forms a part of the efforts to overcome the low performance of organic materials."

PNU Researchers Reveal Cutibacterium acnes as a Potential Cause of Lichen Striatus Hypopigmentation

Retrieved on: 
Wednesday, January 17, 2024

The gram-positive bacterium Cutibacterium acnes has previously been associated with various skin conditions, including acne vulgaris and post-inflammatory hypopigmentation.

Key Points: 
  • The gram-positive bacterium Cutibacterium acnes has previously been associated with various skin conditions, including acne vulgaris and post-inflammatory hypopigmentation.
  • There could, therefore, be a potential association between C. acnes and the observed skin microbiota of patients with LS with and without hypopigmentation.
  • Comparing patients with LS with and without hypopigmentation, the researchers discovered a quadrupled presence (23.26% versus 5.29% of the entire microbiota) of Cutibacterium acnes in the former.
  • Title of original paper: Association between the skin microbiome and lichen striatus hypopigmentation: Cutibacterium acnes as a potential cause